In vitro generation of an HTLV-III variant by neutralizing antibody. NLM AIDSLINE Important note: Information in this article was accurate in 1987. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


In vitro generation of an HTLV-III variant by neutralizing antibody.

J Immunol. 1986 Nov 15;137(10):3306-9. Unique Identifier : AIDSLINE MED/87034962
Robert-Guroff M; Reitz MS Jr; Robey WG; Gallo RC

Abstract: Transmission and culture of parental virus (HTLV-III) from H9 cells transfected with the cloned isolate (lambda HXB-2D) in human serum possessing HTLV-III neutralizing antibody selected for a variant that was not neutralized by the selecting serum but was neutralized by another antibody-positive serum Control virus, selected in serum lacking neutralizing antibody, and the variant showed highly similar tryptic peptide maps of the major envelope glycoprotein, and no changes in restriction enzyme patterns of viral DNA. These findings show that HTLV-III type-specific neutralizing antibodies occur, can influence the propagation of variant viruses that may arise, and presumably result from minor changes in the eliciting antigen. The extent to which such type-specific neutralizing antibodies influence immune surveillance against HTLV-III infection in vivo, a question with relevance to future vaccination attempts, remains to be determined. Nucleotide sequencing of the control and variant envelope genes may elucidate a region important for virus neutralization and vaccine development.
Keywords: Antibodies, Viral/IMMUNOLOGY DNA, Viral/GENETICS HIV/GENETICS/*IMMUNOLOGY Neutralization Tests Peptide Fragments/ANALYSIS Selection (Genetics) Viral Envelope Proteins/IMMUNOLOGY JOURNAL ARTICLE

KWDantibodies,viral/immunologydna,viral/geneticshiv/genetics/KWDimmunologyneutralizationtestspeptidefragments/analysisselection(genetics)viralenvelopeproteins/immunologyjournalarticle
870228
M8720175

Copyright © 1987 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1987. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1987. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .